---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-241930"
form_type: "8-K"
ticker: "NERV"
cik: "0001598646"
company_name: "Minerva Neurosciences, Inc."
filed_at: "2026-05-27T20:18:04+00:00"
generated_at: "2026-05-27T20:20:13.127688+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Minerva enters $75M ATM offering; Phase 3 roluperidone relapse phase extended to 52 weeks

## Summary
- Up to $75M in common stock may be sold at-the-market through Leerink Partners; 3% commission.
- Phase 3 C19 trial relapse assessment phase extended from 40 to 52 weeks after FDA feedback.
- Topline efficacy results from C19 trial expected H2 2027; relapse data expected H2 2028.
- No obligation to sell any shares; program provides capital-raising flexibility.

## SEC filing metadata
- accession: 0001193125-26-241930
- form_type: 8-K
- ticker: NERV
- cik: 0001598646
- company_name: Minerva Neurosciences, Inc.
- filed_at: 2026-05-27T20:18:04+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1598646/000119312526241930/0001193125-26-241930-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1598646/000119312526241930/d119518d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-241930
- JSON: https://secwatch.observer/filing/0001193125-26-241930.json
- Plain text: https://secwatch.observer/filing/0001193125-26-241930.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.